Efficacy of Clinical and Pathogenetic Treatment of Patients with Alopecia Areata Associated with Metabolic Syndrome
October 2023
in “
Perinatology and reproductology from research to practice
”
TLDR Combining medication for dyslipidemia and insulin resistance with basic therapy improves outcomes for alopecia areata with metabolic syndrome.
The study evaluated a treatment method for alopecia areata (AA) associated with metabolic syndrome (MS) in 59 patients, focusing on correcting dyslipidemia and insulin resistance. Patients were divided into four groups, receiving various combinations of basic therapy, rosuvastatin, thioctacid, and dietary adjustments. Results showed that group 1C, which received both rosuvastatin and thioctacid, had the most significant improvements in metabolic indicators and the highest rates of clinical recovery after 6 and 12 months. The study concluded that a pathogenetically substantiated treatment approach, combining medication for dyslipidemia and insulin resistance with basic AA therapy, was effective in improving outcomes for patients with AA and MS.